Ranbaxy set to profit from 180-day US exclusivity for generic Aricept
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories stands to make significant revenue gains in the US after the FDA granted it sole initial rights to sell its generic version of Eisai's Alzheimer's disease drug, Aricept (donepezil hydrochloride), upon patent expiry in late November.